EUSA Portfolio

EUSA Pharma is a specialty pharmaceutical company with a strong and growing portfolio of specialized hospital medicines. The first of these, Rapydan®, was launched in the spring of 2007 in Sweden.

The company’s key marketed products, Caphosol®, Collatamp®, Erwinase®, Fomepizole, Kidrolase®, ProstaScint®, Rapydan®, Quadramet® and Xenazine®, are focused on the areas of oncology, pain control and critical care. Erwinase® is made available to investigators under a Treatment IND in the United States.

In addition EUSA has an active late-stage development pipeline which includes candidates targeting the prevention of infected skin ulcers and local post-surgical pain control.

To complement these existing portfolio products EUSA Pharma is implementing a program of targeted mergers, acquisitions and partnerships to extend its portfolio within its target European and North American markets.

Contact us:
Business Development
Country Offices

For information on our products, where they are available and prescribing information, please see the Product Summary table.